2196 — Shanghai Fosun Pharmaceutical Co Share Price
- HK$30.57bn
- HK$65.28bn
- CNY41.40bn
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 7.18 | ||
PEG Ratio (f) | 0.19 | ||
EPS Growth (f) | 62.79% | ||
Dividend Yield (f) | 3.85% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.62 | ||
Price to Tang. Book | 1.62 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 0.68 | ||
EV to EBITDA | 12.2 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 4.14% | ||
Return on Equity | 5.29% | ||
Operating Margin | 7.98% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CNYm | 28,585.15 | 30,306.98 | 39,005.09 | 43,951.55 | 41,399.54 | 45,036.25 | 49,006.96 | 10.69% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -11.91 | +61.69 | -10.61 | +8.37 | -48.48 | +101.93 | +18.44 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products are mainly applied in the treatment of metabolism and digestive tract system, cardiovascular system, central nervous system, blood system, anti-tumor and anti-infection diseases. The Company is also engaged in medical equipment and medical diagnosis business, as well as the provision of medical services. It distributes its products primarily in domestic and overseas markets.
Directors
- Yifang Wu CHM (52)
- Shengli Li PRE (47)
- Jingping Mei PRE (51)
- Yuqing Chen CPR (45)
- Deyong Wen CPR (50)
- Kexin Wang VCH (57)
- Xiaohui Guan VCH (50)
- Xiaolei Wu CFO (42)
- Qingui Bao SVP (36)
- Rongli Feng SVP (45)
- Hang Hu SVP (37)
- Dongjiu Li SVP (56)
- Yi Liu SVP (46)
- Donghua Wang SVP (52)
- Xiaoxian Dong VPR (40)
- Hao Ji VPR (48)
- Li Su VPR (50)
- Ning Yuan VPR (44)
- Yuejian Zhang VPR (51)
- Yue Zhu VPR (44)
- Aimin Hui OTH (47)
- Qiyu Chen NED
- Donghui Pan NED (51)
- Xiaoliang Xu NED (47)
- Fang Yao NED (51)
- Tianyou Huang NID (61)
- Xian Jiang NID (67)
- Ling Li NID (60)
- Guliang Tang NID (58)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 31st, 1995
- Public Since
- August 7th, 1998
- No. of Shareholders
- 298,973
- No. of Employees
- 40,370
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 2,672,398,711
- Address
- Building A, No. 1289 Yishan Road, SHANGHAI, 200233
- Web
- https://www.fosunpharma.com/
- Phone
- +86 2133987870
- Contact
- Xiaoxian Dong
- Auditors
- Ernst & Young Hua Ming
Latest News for 2196
Upcoming Events for 2196
Similar to 2196
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:08 UTC, shares in Shanghai Fosun Pharmaceutical Co are trading at HK$11.44. This share price information is delayed by 15 minutes.
Shares in Shanghai Fosun Pharmaceutical Co last closed at HK$11.44 and the price had moved by -51.22% over the past 365 days. In terms of relative price strength the Shanghai Fosun Pharmaceutical Co share price has underperformed the FTSE Developed Asia Pacific Index by -49.08% over the past year.
The overall consensus recommendation for Shanghai Fosun Pharmaceutical Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.
The Shanghai Fosun Pharmaceutical Co dividend yield is 2.55% based on the trailing twelve month period.
Last year, Shanghai Fosun Pharmaceutical Co paid a total dividend of CNY0.27, and it currently has a trailing dividend yield of 2.55%. We do not have any data on when Shanghai Fosun Pharmaceutical Co is to next pay dividends.
We do not have data on when Shanghai Fosun Pharmaceutical Co is to next pay dividends. The historic dividend yield on Shanghai Fosun Pharmaceutical Co shares is currently 2.55%.
To buy shares in Shanghai Fosun Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$11.44, shares in Shanghai Fosun Pharmaceutical Co had a market capitalisation of HK$30.57bn.
Here are the trading details for Shanghai Fosun Pharmaceutical Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2196
Based on an overall assessment of its quality, value and momentum Shanghai Fosun Pharmaceutical Co is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Shanghai Fosun Pharmaceutical Co is HK$19.13. That is 67.21% above the last closing price of HK$11.44.
Analysts covering Shanghai Fosun Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of CNY1.39 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shanghai Fosun Pharmaceutical Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -39.02%.
As of the last closing price of HK$11.44, shares in Shanghai Fosun Pharmaceutical Co were trading -32.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Shanghai Fosun Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 7.18. The shares last closed at HK$11.44.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Shanghai Fosun Pharmaceutical Co's management team is headed by:
- Yifang Wu - CHM
- Shengli Li - PRE
- Jingping Mei - PRE
- Yuqing Chen - CPR
- Deyong Wen - CPR
- Kexin Wang - VCH
- Xiaohui Guan - VCH
- Xiaolei Wu - CFO
- Qingui Bao - SVP
- Rongli Feng - SVP
- Hang Hu - SVP
- Dongjiu Li - SVP
- Yi Liu - SVP
- Donghua Wang - SVP
- Xiaoxian Dong - VPR
- Hao Ji - VPR
- Li Su - VPR
- Ning Yuan - VPR
- Yuejian Zhang - VPR
- Yue Zhu - VPR
- Aimin Hui - OTH
- Qiyu Chen - NED
- Donghui Pan - NED
- Xiaoliang Xu - NED
- Fang Yao - NED
- Tianyou Huang - NID
- Xian Jiang - NID
- Ling Li - NID
- Guliang Tang - NID